Reporting owner · CIK 0001106578
Rothblatt Martine A
Visual SEC Form 4 history across 2 companies, 389 transactions and 29 filings.
CHAIR, CEOChairperson & CEOUNITED THERAPEUTICS Corp
Open-market mix
0%buys
Open-market buy performance
90-day forward return on this insider's open-market purchases
Forward return is not available yet
We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for some of their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.
Monthly open-market activity
Reported purchase and sale transaction counts
Buys Sells
Net value flow
Buys minus sells
Jan 26
$0
Mar 26
−$65.4M
May 26
−$9.1M
Aug 26
−$49M
Sep 26
−$9.5M
Transaction texture
Ownership and ticket size
Average P/S size$413.6K
Median P/S size$303.6K
Direct242
Indirect147
Sep 03, 2026exercise
Filing-only signals
Deterministic matches in this insider's history
Latest Form 4 facts
Quick context from source filings
Latest transaction
sale at UNITED THERAPEUTICS Corp on Sep 03, 2026 valued at $20,632.
Review SEC filingAssociated companies
Visual map of known reporting history
| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| UTHR | ROTHBLATT MARTINE A | CHAIRCEO | sale10b5-1 | 717 | -$40.9M | S | −9.2% | 05/27 | 05/26 | |
| UTHR | ROTHBLATT MARTINE A | CHAIRCEO | sale10b5-1 | 683 | -$38.9M | S | −9.2% | 05/27 | 05/26 | |
| UTHR | ROTHBLATT MARTINE A | CHAIRCEO | sale10b5-1 | 642 | -$36.5M | S | −9.2% | 05/27 | 05/26 | |
| UTHR | ROTHBLATT MARTINE A | CHAIRCEO | sale10b5-1 | 958 | -$54.4M | S | −9.2% | 05/27 | 05/26 | |
| UTHR | ROTHBLATT MARTINE A | CHAIRCEO | sale10b5-1 | 520 | -$29.5M | S | −9.2% | 05/27 | 05/26 | |
| UTHR | ROTHBLATT MARTINE A | CHAIRCEO | sale10b5-1 | 320 | -$18.1M | S | −9.2% | 05/27 | 05/26 | |
| UTHR | ROTHBLATT MARTINE A | CHAIRCEO | sale10b5-1 | 240 | -$13.5M | S | −9.2% | 05/27 | 05/26 | |
| UTHR | ROTHBLATT MARTINE A | CHAIRCEO | sale10b5-1 | 40 | -$2.24M | S | −9.2% | 05/27 | 05/26 | |
| UTHR | ROTHBLATT MARTINE A | CHAIRCEO | sale10b5-1 | 35 | -$1.96M | S | −9.2% | 05/27 | 05/26 | |
| UTHR | ROTHBLATT MARTINE A | CHAIRCEO | sale10b5-1 | 45 | -$2.52M | S | −9.2% | 05/27 | 05/26 |
Rothblatt Martine A Insider Activity FAQ
SEC Form 4 context
Who is Rothblatt Martine A?
Rothblatt Martine A is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001106578.
Which companies has Rothblatt Martine A reported transactions for?
UNITED THERAPEUTICS Corp, BETA Technologies, Inc.
When was Rothblatt Martine A's latest insider buy?
buy at UNITED THERAPEUTICS Corp on May 26, 2026 valued at $863,947.
When was Rothblatt Martine A's latest insider sale?
sale at UNITED THERAPEUTICS Corp on Sep 03, 2026 valued at $20,632.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.